PMID- 28383130
OWN - NLM
STAT- MEDLINE
DCOM- 20170728
LR  - 20170728
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 92
IP  - 8
DP  - 2017 Aug
TI  - Clinical characteristics and prognostic factors in multiple myeloma patients with 
      light chain deposition disease.
PG  - 739-745
LID - 10.1002/ajh.24756 [doi]
AB  - Light chain deposition disease (LCDD) is characterized by monotypic 
      immunoglobulin depositions which will eventually lead to loss of organ function 
      if left untreated. While the kidney is almost always affected, the presence and 
      degree of LCDD in other organs vary. Ten to thirty percent of LCDD patients have 
      underlying Multiple Myeloma (MM), yet outcome and prognostic markers in this 
      particular patient group are still lacking. Here, we analyzed 69 patients with MM 
      and biopsy proven LCDD and report on renal and extra-renal involvement and its 
      impact on prognosis as well as renal response depending on hematologic response. 
      Coexisting light chain diseases such as AL amyloid and cast nephropathy were 
      found in 30% of patients; those with LCDD and concurrent amyloid tended to have 
      shorter survival. Cardiac involvement by LCDD was seen in one-third of our 
      patients and was associated with shorter overall survival; such patients also had 
      a significantly higher risk of treatment-related mortality (TRM) after stem cell 
      transplant (SCT) compared to LCDD patients without cardiac involvement. This 
      study highlights that MM patients with LCDD present with different clinical 
      features compared to previously reported LCDD cohorts. Rapid initiation of 
      treatment is necessary to prevent progressive renal disease and worse outcome. 
      Coexisting light chain diseases and cardiac involvement are more common than 
      previously reported and confer worse clinical outcome, emphasizing the need for 
      careful patient careful patient evaluation and treatment selection.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Mohan, Meera
AU  - Mohan M
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Buros, Amy
AU  - Buros A
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Mathur, Pankaj
AU  - Mathur P
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Gokden, Neriman
AU  - Gokden N
AD  - Department of Pathology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas.
FAU - Singh, Manisha
AU  - Singh M
AD  - Division for Nephrology, Department of Medicine, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas.
FAU - Susanibar, Sandra
AU  - Susanibar S
AUID- ORCID: 0000-0003-0703-2518
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Jo Kamimoto, Jorge
AU  - Jo Kamimoto J
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Hoque, Shadiqul
AU  - Hoque S
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Radhakrishnan, Muthukumar
AU  - Radhakrishnan M
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Matin, Aasiya
AU  - Matin A
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Davis, Cynthia
AU  - Davis C
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Grazziutti, Monica
AU  - Grazziutti M
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Thanendrarajan, Sharmilan
AU  - Thanendrarajan S
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - van Rhee, Frits
AU  - van Rhee F
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Zangari, Maurizio
AU  - Zangari M
AUID- ORCID: 0000-0002-1720-3854
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Davies, Faith
AU  - Davies F
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Morgan, Gareth
AU  - Morgan G
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Epstein, Joshua
AU  - Epstein J
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Barlogie, Bart
AU  - Barlogie B
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
FAU - Schinke, Carolina
AU  - Schinke C
AUID- ORCID: 0000-0002-2699-1741
AD  - Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas.
LA  - eng
PT  - Journal Article
DEP - 20170601
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin Light Chains)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers
MH  - Biopsy
MH  - Bone Marrow/metabolism/pathology
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Immunoglobulin Light Chains/*metabolism
MH  - Kidney Diseases/etiology/pathology/physiopathology
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/complications/*diagnosis/*metabolism/therapy
MH  - Myocardium/metabolism/pathology
MH  - Prognosis
MH  - *Protein Aggregation, Pathological
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2017/04/07 06:00
MHDA- 2017/07/29 06:00
CRDT- 2017/04/07 06:00
PHST- 2016/10/05 00:00 [received]
PHST- 2017/03/24 00:00 [revised]
PHST- 2017/04/03 00:00 [accepted]
PHST- 2017/04/07 06:00 [pubmed]
PHST- 2017/07/29 06:00 [medline]
PHST- 2017/04/07 06:00 [entrez]
AID - 10.1002/ajh.24756 [doi]
PST - ppublish
SO  - Am J Hematol. 2017 Aug;92(8):739-745. doi: 10.1002/ajh.24756. Epub 2017 Jun 1.